首页 | 本学科首页   官方微博 | 高级检索  
     


Expression of pim-1 in Tumors,Tumor Stroma and Tumor-Adjacent Mucosa Co-Determines the Prognosis of Colon Cancer Patients
Authors:Yong-hai Peng  Jian-jun Li  Fang-wei Xie  Jian-fang Chen  Ying-hao Yu  Xue-nong Ouyang  Hou-jie Liang
Affiliation:1. Department of Oncology, Southwest Hospital, Third Military Medical University, Chongqing, People’s Republic of China.; 2. Department of Oncology, Fuzhou General Hospital, Fuzhou, People’s Republic of China.; 3. Department of Pathology, Fuzhou General Hospital, Fuzhou, People’s Republic of China.; Kyushu University Faculty of Medical Science, Japan,
Abstract:Provirus integration site for Moloney murine leukemia virus (pim-1) is a proto-oncogene that is linked to the development and progression of several cancers. In this study, we evaluated pim-1 expression in tumors, tumor stroma and tumor-adjacent mucosa together as an independent prognostic factor for colon cancer patients. The study included 343 colon cancer patients. Immunohistochemical staining was used to detect pim-1. Multivariate cox regression for disease-free survival (DFS) were used to identify independent prognostic factors. Analytic hierarchy process (AHP) was used to calculate the weight of pim-1 in tumors, tumor stroma and tumor-adjacent mucosa in order to obtain a Pim-1 total score (PTS) for recurrence and survival. Kaplan–Meier DFS curves and OS curves for patients with different pim-1 expression levels were compared using the log-rank test. In this study, four independent prognostic factors were identified for colon cancer patients: pim-1 expression in tumors, tumor stroma, tumor-adjacent mucosa, as well as tumor stage. It has been established that clinical stage is an important prognostic factor for colon cancer patients. However, PTS can identify the patients who are likely to recur not only in the whole radical excision group but also within each stage of this group. Based on the results of this study we can conclude that the PTS combined with clinical staging system may be a better predictor of colon cancer patients’ prognosis than using the clinical stage system alone.Clinical Trials Gov. Number: ChiCTR-PRCH-12002842
Keywords:
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号